UNSPSC 51201601: Anthrax antigen

This clasification denotes preparations recognized by the immune system and which induce an immune reaction to an acute infection caused by the spore-forming bacteria bacillus anthracis, an infection called anthrax. It commonly affects hoofed animals such as sheep and goats. Infection in humans often involves the skin (cutaneous anthrax), the lungs (inhalation anthrax), or the gastrointestinal tract. Anthrax is not contagious and can be treated with antibiotics.

UNSPSC 51201601 Anthrax antigen, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The single recent opportunity posted under this code—a July 2026 notice from the Mississippi State Department of Health—concerns Yellow Fever Vaccine from Sanofi Pasteur, Inc., which falls outside the anthrax-antigen classification. State and local procurement offices do not appear to be actively soliciting anthrax antigen through routine competitive channels at this time, and the mismatch between the code's stated product and the sole Yellow Fever Vaccine notice suggests either categorical mistagging or extremely limited demand for anthrax-related biologics in the state and local market.

The Mississippi State Department of Health posted a sole source procurement notice (Solicitation 3150006922) on July 13, 2026, with an objection deadline of August 3, 2026 at 10:00 a.m. CST. The notice invited written objections to sole source classification, with submissions directed to Cynthia Brasher at the department's Purchasing Department. No quantity, contract term, estimated value, or pricing was specified in the notice. If the department received and substantiated alternative-source objections, it would withdraw the sole source designation and conduct a competitive bid or selection process; absent such objections, the department would appeal to the Public Procurement Review Board. The absence of recent competitive solicitations or open-market activity under this code suggests low current pursuit potential unless your firm has specialized capability in anthrax-antigen production or related biological products that state health departments may source through mechanisms not yet reflected in recent postings.